Stockscreener 앱 받기
0.2375
13.57%
-0.1825
전일 마감가:
$0.42
열려 있는:
$0.23
하루 거래량:
888
Relative Volume:
66.00
시가총액:
$N/A
수익:
-
순이익/손실:
$-10.38M
주가수익비율:
-0.0623
EPS:
-3.81
순현금흐름:
$-12.45M
1주 성능:
-13.57%
1개월 성능:
-70.96%
6개월 성능:
-83.79%
1년 성능:
-96.88%
1일 변동 폭
$0.2243
$0.2473
1주일 범위
$0.2243
$0.2473
52주 변동 폭
$0.2243
$0.2473
Avenue Therapeutics Inc Stock (ATXI) Company Profile
ATXI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.2473 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.71 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
658.26 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.69 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.06 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스
Avenue Therapeutics Ends License Agreement with AnnJi - TipRanks
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews
CBLI Back On Track, HTBX Joins Hands With OncoSec, PRAH In Good Health - RTTNews
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow
AVENUE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI - The Manila Times
Oncotelic Therapeutics Publishes New Research Demonstrating - GlobeNewswire
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks - The Globe and Mail
eXp World (EXPI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
1 Technology ETF to Buy Hand Over Fist and 1 to Avoid - The Globe and Mail
North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs - Marketscreener.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience With Investment in Click Therapeutics for Digital Therapeutics Beyond Clinical Trials - Yahoo Finance
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Decline in Short Interest - Defense World
Atlanticus Holdings Co. 9.25% Senior Notes due 2029 (NASDAQ:ATLCZ) Short Interest Update - Defense World
AVENUE THERAPEUTICS Earnings Preview: Recent $ATXI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Avenue Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Postoperative Pain Clinical Pipeline | 45+ Companies, - openPR
Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com India
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Episode 203Curtis Oltmans - Audacy
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute By Investing.com - Investing.com South Africa
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com India
Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World
Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World
American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World
Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World
Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com
Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World
Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World
February’s Top 3 Stock Upgrades: What Investors Need to Know - The Globe and Mail
Avenue Therapeutics Inc (ATXI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):